Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of a programmed death-1 checkpoint inhibitor in a case of cutaneous squamous cell carcinoma harboring mutations of TP53 and BRCA2.

Dermatologic therapy - 1 Nov 2020

Ma Wei-Li, Chou Chen-Han, Chen Jo-Pai, Kuo Sung-Hsin

Abstract excerpt

Immune checkpoint blockades were reported to result in clinical responses in inoperable and metastatic cutaneous squamous cell carcinoma (cSCC). This report describes an 87-year-old woman with recurrent cSCC that was initially responsive to cetuximab (the monoclonal antibody against epithelial growth factor receptor) but eventually became refractory to cetuximab and multiple subsequent salvage chemotherapy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA2 Protein

Share to Carcinoma, Squamous Cell

Share to Mutation

Share to Neoplasm Recurrence, Local

Share to Skin Neoplasms

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 32683791
DOI: 10.1111/dth.14035

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of a programmed death-1 checkpoint inhibitor in a case of cutaneous squamous cell carcinoma harboring mutations of TP53 and BRCA2.PMID 32683791Read ↗

Genomic analysis of metastatic cutaneous squamous cell carcinoma.Semantic proximity Read ↗

Establishment and molecular characterization of HCB-541, a novel and aggressive human cutaneous squamous cell carcinoma cell line.Semantic proximity Read ↗

Differential mutation frequencies in metastatic cutaneous squamous cell carcinomas versus primary tumors.Semantic proximity Read ↗

Recurrent squamous cell carcinoma and a novel mutation in a patient with xeroderma pigmentosum: a case report.Semantic proximity Read ↗

Metastatic cutaneous squamous cell carcinoma shows frequent deletion in the protein tyrosine phosphatase receptor Type D gene.Semantic proximity Read ↗

Case report of penile squamous cell carcinoma continuous treatment with BRCA2 mutation.Semantic proximity Read ↗

Association of Oncogenic Mutations in Patients With Advanced Cutaneous Squamous Cell Carcinomas Treated With Cetuximab.Semantic proximity Read ↗

Epidermal Growth Factor Receptor P753S Mutation in Cutaneous Squamous Cell Carcinoma Responsive to Cetuximab-Based Therapy.Semantic proximity Read ↗

Eribulin inhibits growth of cutaneous squamous cell carcinoma cell lines and a novel patient-derived xenograftSemantic proximity Read ↗

Lasting Complete Clinical Response of a Recurring Cutaneous Squamous Cell Carcinoma With MEK Mutation and PIK3CA Amplification Achieved by Dual Trametinib and Metformin Therapy.Semantic proximity Read ↗

FGFR Inhibition Overcomes Resistance to EGFR-targeted Therapy in Epithelial-like Cutaneous Carcinoma.Semantic proximity Read ↗

A Prospective Study Investigating the Efficacy and Toxicity of Definitive ChemoRadadiation and ImmunOtherapy (CRIO) in Locally and/or Regionally Advanced Cutaneous Squamous Cell Carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.